Please Wait.....
Report
Global Markets and Manufacturing Technologies for Protein Drugs
Market Research Report I 2025-04-30 I 162 Pages I BCC Research
Description
Report Scope
The report analyzes trends in the global market for protein drugs and manufacturing technologies. The report includes global revenue ($ millions) for the base year of 2023 and estimated data for the forecast period of 2024 through 2029. The market is segmented by product type/subtype, manufacturing technology and region. The regions covered are North America, Europe, Asia-Pacific and the Rest of the World, focusing on major countries in these regions.
The report focuses on the trends and challenges that affect the market and the vendor landscape. It analyzes environmental, social, and corporate governance (ESG) developments and discusses patents and emerging technologies related to the market.
The report concludes with an analysis of the competitive landscape, which provides the rankings and market shares of leading companies in the protein drug market. It also has a section of company profiles that shows financials, product portfolios and recent developments.
Report Includes
- 79 data tables and 57 additional tables
- An analysis of the global markets for protein drugs and their manufacturing technologies
- Analyses of the global market trends, with revenue data for 2021 to 2023, estimates for 2024, and projected CAGRs through 2029
- Estimates of the size of and revenue prospects for the global market, along with a market share analysis by type of protein drug, manufacturing technology, and region
- Facts and figures pertaining to the market dynamics, technological advances, regulations, and the impact of macroeconomic factors
- Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses
- Analysis of the advances in manufacturing technologies, disease prevalence trends, new products , and the impact of biosimilars entering the market for protein drugs
- An analysis of patents and significant patent grants
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
- Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
- Profiles of leading companies, including AbbVie Inc., Bristol Myer Squibb, Merck & Co., Novo Nordisk S/A, Sanofi, and Roche
Executive Summary
Summary:
The global protein drugs market is expected to grow from $441.7 billion in 2024 and is projected to reach $655.7 billion by the end of 2029, at a compound annual growth rate (CAGR) of 8.2% during the forecast period of 2024 to 2029.
Therapeutic proteins are a class of medicines that help treat a number of indications, such as cancer, diabetes, stroke, anemia and hemophilia. Protein drugs perform particular and complex functions compared to small molecules. Due to the high specificity, these protein drugs are less toxic and less likely to interfere with normal biological processes. Protein drugs can be manufactured in many ways, but most proteins are produced through recombinant deoxyribonucleic acid (rDNA) technology, using bacteria, yeast or mammalian cells as the host system.
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Chapter 2 Market Overview
Current and Future Market Overview
Technology Background
Pharmacological Classification of Therapeutic Proteins
Protein Therapeutics with Enzymatic or Regulatory Activity
Protein Therapeutics with Special Targeting Activity
Protein Vaccines
Characteristics of Therapeutic Proteins
Macroeconomic Factors
Porter's Five Forces Analysis
Potential for New Entrants
Bargaining Power of Suppliers
Bargaining Power of Buyers
Threat of Substitute Products or Services
Competition in the Industry
Supply Chain Analysis
R&D
Manufacturing
Packaging
Wholesale Distributors and Repackagers
Pharmacies/Hospitals
Dispensed to Consumers
Chapter 3 Market Dynamics
Global Market Dynamics
Market Drivers
Advances in Manufacturing Technologies
Continuous Product Launches
Increasing Incidence of Cancer
Market Restraints
High Costs of Protein Drugs
Complex Regulatory Procedures
Market Challenges
Patent Expiration and Loss of Exclusivity
Protein Drugs Stability and Delivery
Market Opportunities
Increasing Number of Approvals for MAbs
Licensing and Collaboration Agreements
Chapter 4 Regulatory Landscape
Regulatory Scenario
Price Regulations
Chapter 5 Emerging Technologies
Overview
Emerging Technologies in Protein Drugs Market
Bispecific Antibodies and Multi-Specific Antibodies
Antibody-Drug Conjugates
Antibody Fusion Proteins
AI in the Protein Drug Market
Chapter 6 Market Segment Analysis
Overview
Segmentation Breakdown
Global Market for Protein Drugs, by Type
MAbs
Peptide Hormones
Vaccines
Blood Factors
Cytokines
Therapeutic Enzymes
Peptide Antibiotics
Fusion Proteins
Global Market for Protein Drugs, by Manufacturing Technology
Cell Culture
Microbial Fermentation
Natural Source
Embryonated Egg
Chemical Synthesis
Transgenics
Market Breakdown by Region
Global Market for Protein Drugs, by Region
North America
Europe
Asia-Pacific
Rest of the World
Chapter 7 Competitive Intelligence
Industry Structure
Leading Protein Drugs, 2023
Market Share Analysis
MAbs
Peptide Hormones
Strategic Analysis
Acquisitions
Product Approvals
Agreements and Partnerships
Other Strategies
Chapter 8 Sustainability in the Protein Drug Market: ESG Perspective
Sustainability in the Protein Drug Industry
ESG Risk Ratings: Understanding the Data
ESG Performance Analysis
Environmental Performance
Social Performance
Governance Performance
Concluding Remarks
Chapter 9 Appendix
Methodology
Abbreviations
References
Company Profiles
ABBVIE INC.
AMGEN INC.
ASTRAZENECA
BAYER AG
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
JOHNSON & JOHNSON SERVICES INC.
LILLY
MERCK & CO. INC.
NOVARTIS AG
NOVO NORDISK A/S
PFIZER INC.
REGENERON PHARMACEUTICALS INC.
SANOFI
TAKEDA PHARMACEUTICAL CO. LTD.
List of Tables
Summary Table : Global Market for Protein Drugs, by Region, Through 2029
Table 1 : Evolution of Therapeutic Proteins, 1950s to Present
Table 2 : Global Cancer Incidence and Mortality Cases, by WHO Region, 2022
Table 3 : Therapeutic Area Distribution of Approved Antibody Drugs, 2023*
Table 4 : Global Market for Protein Drugs, by Type, Through 2029
Table 5 : Global Market for MAbs, by Type, Through 2029
Table 6 : Global Market for MAbs, by Region, Through 2029
Table 7 : Global Market for Human MAbs, by Region, Through 2029
Table 8 : Global Market for Humanized MAbs, by Region, Through 2029
Table 9 : Global Market for Chimeric MAbs, by Region, Through 2029
Table 10 : Global Market for Murine MAbs, by Region, Through 2029
Table 11 : Global Market for Peptide Hormones, by Type, Through 2029
Table 12 : Global Market for Peptide Hormones, by Region, Through 2029
Table 13 : Global Market for Insulin, by Region, Through 2029Global Market for Insulin, by Region, Through 2029
Table 14 : Global Market for EPO, by Region, Through 2029
Table 15 : Global Market for Growth Hormones, by Region, Through 2029
Table 16 : Global Market for Other Peptide Hormones, by Region, Through 2029
Table 17 : Global Market for Protein Vaccines, by Type, Through 2029
Table 18 : Global Market for Protein Vaccines, by Region, Through 2029
Table 19 : Global Market for Bacterial Vaccines, by Region, Through 2029
Table 20 : Global Market for Viral Vaccines, by Region, Through 2029
Table 21 : Global Market for Other Protein Vaccines, by Region, Through 2029
Table 22 : Global Market for Blood Factors, by Type, Through 2029
Table 23 : Global Market for Blood Factors, by Region, Through 2029
Table 24 : Global Market for Coagulation Factors, by Region, Through 2029
Table 25 : Global Market for Immunoglobulins, by Region, Through 2029
Table 26 : Global Market for Other Blood Factors, by Region, Through 2029
Table 27 : Global Market for Cytokines, by Type, Through 2029
Table 28 : Global Market for Cytokines, by Region, Through 2029
Table 29 : Global Market for Interleukins, by Region, Through 2029
Table 30 : Global Market for Interferons, by Region, Through 2029
Table 31 : Global Market for G-CSF, by Region, Through 2029
Table 32 : Global Market for Therapeutic Enzymes, by Type, Through 2029
Table 33 : Global Market for Therapeutic Enzymes, by Region, Through 2029
Table 34 : Global Market for Lysosomal Enzymes, by Region, Through 2029
Table 35 : Global Market for Thrombolytic Enzymes, by Region, Through 2029
Table 36 : Global Market for Pancreatic Enzymes, by Region, Through 2029
Table 37 : Global Market for Peptide Antibiotics, by Type, Through 2029
Table 38 : Global Market for Peptide Antibiotics, by Region, Through 2029
Table 39 : Global Market for Cyclosporine, by Region, Through 2029
Table 40 : Global Market for Vancomycin, by Region, Through 2029
Table 41 : Global Market for Other Peptide Antibiotics, by Region, Through 2029
Table 42 : Global Market for Fusion Proteins, by Region, Through 2029
Table 43 : Global Market for Protein Drugs, by Manufacturing Technology, Through 2029
Table 44 : Global Market for Cell Culture, by Region, Through 2029
Table 45 : Global Market for Microbial Fermentation, by Region, Through 2029
Table 46 : Global Market for Natural Source Protein Manufacturing Technology, by Region, Through 2029
Table 47 : Global Market for Embryonated Egg Protein Manufacturing Technology, by Region, Through 2029
Table 48 : Global Market for Chemical Synthesis Protein Manufacturing Technology, by Region, Through 2029
Table 49 : Global Market for Transgenics Protein Manufacturing Technology, by Region, Through 2029
Table 50 : Global Market for Protein Drugs, by Region, Through 2029
Table 51 : North American Market for Protein Drugs, by Type, Through 2029
Table 52 : North American Market for Protein Drugs, by Manufacturing Technology, Through 2029
Table 53 : North American Market for Protein Drugs, by Country, Through 2029
Table 54 : Estimated Incidence of Cancer Cases in the EU, by Country, 2022
Table 55 : Therapeutic MAbs Approved or Under Review in the EU, 2023 and 2024
Table 56 : European Market for Protein Drugs, by Type, Through 2029
Table 57 : European Market for Protein Drugs, by Manufacturing Technology, Through 2029
Table 58 : European Market for Protein Drugs, by Country, Through 2029
Table 59 : Asia-Pacific Market for Protein Drugs, by Type, Through 2029
Table 60 : Asia-Pacific Market for Protein Drugs, by Manufacturing Technology, Through 2029
Table 61 : Asia-Pacific Market for Protein Drugs, by Country, Through 2029
Table 62 : RoW Market for Protein Drugs, by Type, Through 2029
Table 63 : RoW Market for Protein Drugs, by Manufacturing Technology, Through 2029
Table 64 : RoW Market for Protein Drugs, by Sub-Region, Through 2029
Table 65 : Leading Protein Drugs, 2023
Table 66 : Acquisitions in the Protein Drug Market, 2022-2024
Table 67 : Product Approvals in the Protein Drug Market, 2022-2024
Table 68 : Agreements and Partnerships in the Protein Drug Market, 2022-2025
Table 69 : Other Strategies in the Protein Drug Market, 2022-2024
Table 70 : Focus Areas in ESG Metrics
Table 71 : ESG Rankings for Major Protein Drug Companies, 2024*
Table 72 : ESG: Environmental Overview
Table 73 : ESG: Social Factors Overview
Table 74 : ESG: Governance Overview
Table 75 : Abbreviations Used in this Report
Table 76 : AbbVie Inc.: Company Snapshot
Table 77 : AbbVie Inc.: Financial Performance, FY 2022 and 2023
Table 78 : AbbVie Inc.: Product Portfolio
Table 79 : AbbVie Inc.: News/Key Developments, 2023 and 2024
Table 80 : Amgen Inc.: Company Snapshot
Table 81 : Amgen Inc.: Financial Performance, FY 2022 and 2023
Table 82 : Amgen Inc.: Product Portfolio
Table 83 : Amgen Inc.: News/Key Developments, 2022-2024
Table 84 : AstraZeneca: Company Snapshot
Table 85 : AstraZeneca: Financial Performance, FY 2022 and 2023
Table 86 : AstraZeneca: Product Portfolio
Table 87 : AstraZeneca: News/Recent Developments, 2023 and 2024
Table 88 : Bayer AG: Company Snapshot
Table 89 : Bayer AG: Financial Performance, FY 2022 and 2023
Table 90 : Bayer AG: Product Portfolio
Table 91 : Bayer AG: News/Recent Developments, 2024
Table 92 : Bristol-Myers Squibb Co.: Company Snapshot
Table 93 : Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2023
Table 94 : Bristol-Myers Squibb Co.: Product Portfolio
Table 95 : Bristol-Myers Squibb Co.: News/Key Developments, 2023
Table 96 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 97 : F. Hoffman-La Roche Ltd.: Financial Performance, FY 2022 and 2023
Table 98 : F. Hoffman-La Roche Ltd.: Product Portfolio
Table 99 : F. Hoffman-La Roche Ltd.: News/Key Developments, 2023 and 2024
Table 100 : Johnson & Johnson Services Inc.: Company Snapshot
Table 101 : Johnson & Johnson Services Inc.: Financial Performance, FY 2022 and 2023
Table 102 : Johnson & Johnson Services Inc.: Product Portfolio
Table 103 : Johnson & Johnson Services Inc.: News/Key Developments, 2022?2024
Table 104 : Lilly: Company Snapshot
Table 105 : Lilly: Financial Performance, FY 2022 and 2023
Table 106 : Lilly: Product Portfolio
Table 107 : Lilly: News/Key Developments, 2023 and 2024
Table 108 : Merck & Co. Inc.: Company Snapshot
Table 109 : Merck & Co. Inc.: Financial Performance, FY 2022 and 2023
Table 110 : Merck & Co. Inc.: Product Portfolio
Table 111 : Merck & Co. Inc.: News/Key Developments, 2022-2024
Table 112 : Novartis AG: Company Snapshot
Table 113 : Novartis AG: Financial Performance, FY 2022 and 2023
Table 114 : Novartis AG: Product Portfolio
Table 115 : Novartis AG: News/Key Developments, 2022-2024
Table 116 : Novo Nordisk A/S: Company Snapshot
Table 117 : Novo Nordisk A/S: Financial Performance, FY 2022 and 2023
Table 118 : Novo Nordisk A/S: Product Portfolio
Table 119 : Novo Nordisk A/S: News/Key Developments, 2023-2025
Table 120 : Pfizer Inc.: Company Snapshot
Table 121 : Pfizer Inc.: Financial Performance, FY 2022 and 2023
Table 122 : Pfizer Inc.: Product Portfolio
Table 123 : Pfizer Inc.: News/Key Developments, 2023 and 2024
Table 124 : Regeneron Pharmaceuticals Inc.: Company Snapshot
Table 125 : Regeneron Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
Table 126 : Regeneron Pharmaceuticals Inc.: Product Portfolio
Table 127 : Regeneron Pharmaceuticals Inc.: News/Key Developments, 2022 and 2023
Table 128 : Sanofi: Company Snapshot
Table 129 : Sanofi: Financial Performance, FY 2022 and 2023
Table 130 : Sanofi: Product Portfolio
Table 131 : Sanofi: News/Key Developments, 2022-2024
Table 132 : Takeda Pharmaceutical Co. Ltd.: Company Snapshot
Table 133 : Takeda Pharmaceutical Co. Ltd.: Financial Performance, FY 2022 and 2023
Table 134 : Takeda Pharmaceutical Co. Ltd.: Product Portfolio
Table 135 : Takeda Pharmaceutical Co. Ltd.: News/Key Developments, 2022-2024
List of Figures
Summary Figure : Global Market Shares of Protein Drugs, by Region, 2023
Figure 1 : Desirable Characteristics of Therapeutic Proteins
Figure 2 : Porter's Five Forces Analysis: Protein Drug Market
Figure 3 : Supply Chain of Protein Drugs
Figure 4 : Market Dynamics Snapshot
Figure 5 : Emerging Technologies in the Protein Drugs Market
Figure 6 : Global Market Shares of Protein Drugs, by Type, 2023
Figure 7 : Global Market Shares of MAbs, by Type, 2023
Figure 8 : Global Market Shares of Peptide Hormones, by Type, 2023
Figure 9 : Global Market Shares of Protein Vaccines, by Type, 2023
Figure 10 : Global Market Shares of Blood Factors, by Type, 2023
Figure 11 : Global Market Shares of Cytokines, by Type, 2023
Figure 12 : Global Market Shares of Therapeutic Enzymes, by Type, 2023
Figure 13 : Global Market Shares of Peptide Antibiotics, by Type, 2023
Figure 14 : Global Market Shares of Protein Drugs, by Manufacturing Technology, 2023
Figure 15 : Global Market Shares of Protein Drugs, by Region, 2023
Figure 16 : North American Market Shares of Protein Drugs, by Country, 2023
Figure 17 : U.S. Elderly Population (65 and Older), 2010-2050
Figure 18 : European Market Shares of Protein Drugs, by Country, 2023
Figure 19 : Asia-Pacific Market Shares of Protein Drugs, by Country, 2023
Figure 20 : RoW Market Shares of Protein Drugs, by Sub-Region, 2023
Figure 21 : Global Market Shares of MAbs, by Company, 2023
Figure 22 : Global Market Shares of Peptide Hormones, by Company, 2023
Figure 23 : Business Benefits of a Strong ESG Proposition
Figure 24 : AbbVie Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 25 : AbbVie Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 26 : Amgen Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 27 : Amgen Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 28 : AstraZeneca: Revenue Shares, by Business Unit, FY 2023
Figure 29 : AstraZeneca: Revenue Shares, by Region/Country, FY 2023
Figure 30 : Bayer AG: Revenue Shares, by Business Unit, FY 2023
Figure 31 : Bayer AG: Revenue Shares, by Region/Country, FY 2023
Figure 32 : Bristol-Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2023
Figure 33 : Bristol-Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2023
Figure 34 : F. Hoffman-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2023
Figure 35 : F. Hoffman-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2023
Figure 36 : Johnson & Johnson Services Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 37 : Johnson & Johnson Services Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 38 : Lilly: Revenue Shares, by Business Unit, FY 2023
Figure 39 : Lilly: Revenue Shares, by Country/Region, FY 2023
Figure 40 : Merck & Co. Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 41 : Merck & Co. Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 42 : Novartis AG: Revenue Shares, by Business Unit, FY 2023
Figure 43 : Novartis AG: Revenue Shares, by Country/Region, FY 2023
Figure 44 : Novo Nordisk A/S: Revenue Shares, by Business Unit, FY 2023
Figure 45 : Novo Nordisk A/S: Revenue Shares, by Country/Region, FY 2023
Figure 46 : Pfizer Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 47 : Pfizer Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 48 : Regeneron Pharmaceuticals Inc.: Revenue Shares, by Product Sales, FY 2023
Figure 49 : Regeneron Pharmaceuticals Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 50 : Sanofi: Revenue Shares, by Business Unit, FY 2023
Figure 51 : Sanofi: Revenue Shares, by Country/Region, FY 2023
Figure 52 : Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Business Unit, FY 2023
Figure 53 : Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Region, FY 2023
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security